MannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money.
Latest MannKind news
We have not published a story on MannKind yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $52.9 million, plus short-term investments of $58.2 million, $111.1 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about MannKind
Has MannKind raised money recently?
Our latest story on this, dated Jul 24, 2026: "MannKind closes $50.0 million private placement led by Frazier Life Sciences". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MannKind?
MannKind Corporation trades under the ticker MNKD on NASDAQ.
Where is MannKind listed?
MannKind Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:NNFN; LSX:A2DMZL.
What is the SEC CIK of MannKind?
The SEC Central Index Key (CIK) for MannKind Corporation is 899460. Its filings are on SEC EDGAR.
How many shares does MannKind have outstanding?
321,540,637 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is MannKind listed under?
Our directory records MannKind Corporation under United States.
What does MannKind do?
Our directory classifies MannKind Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of MannKind?
The ISIN recorded for MannKind Corporation is US56400P7069.
Does aibio.space cover MannKind?
aibio.space lists MannKind Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
Where is MannKind incorporated?
SEC records list its state or country of incorporation as DE.
What was MannKind's revenue last year?
$349.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is MannKind profitable?
MannKind Corporation reported net income of $5.9 million for the fiscal year ended Dec 31, 2025, and generated $18.3 million of cash from operations, per its annual report to the SEC.
How much does MannKind spend on research and development?
$66.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does MannKind have?
$111.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest MannKind (MNKD) stock news?
Our latest story on MannKind, dated Jul 24, 2026: "MannKind closes $50.0 million private placement led by Frazier Life Sciences". MannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money. Source.
Investor discussion: MannKind
Members talk about MannKind (MNKD). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at MannKind, newest first. Each line links the filing it comes from.
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). Source
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MNKD on TradingView.
SEC filings and registration
SEC name
Mannkind Corp
CIK
899460
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MNKD (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
1 CASPER STREET, DANBURY, CT, 06810
Phone
818-661-5000
Shares outstanding
321,540,637 as of 2026-07-24 (10-Q filed 2026-08-05)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
MannKind Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MNKD, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio